Case report:

AVELUMAB INDUCING HYPOTHYROIDISM AND HYPOADRENALISM: A CASE REPORT AND REVIEW OF LITERATURE

Kashif Aziz*, Amir Shahbaz, Muhammad Umair, Isaac Sachmechi

Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York

* corresponding author: Kashif Aziz, 9155 97th street, Jamaica, New York, 11421, E-mail: kashifaziz927@gmail.com, Tel: +19293509197, +923464910784

http://dx.doi.org/10.17179/excli2018-1357

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

Avelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Avelumab has recently been approved in the United States, Europe and Japan for treatment of metastatic Merkel cell carcinoma (MCC). Avelumab inhibits the interaction of Programmed cell death protein 1 (PD-1) on immune cells with PD-L1 on tumor cells, thus banishing immunosuppressive signals and leading to enhanced immune cell activation. Here we are revealing a case of the patient with metastatic gastric cancer receiving avelumab with the development of undesirable endocrinopathies during the course of treatment. We suggested that patients receiving avelumab immunotherapy should be monitored for signs and symptoms of thyroiditis, hypothyroidism and adrenal insufficiency, which may require immediate attention and supportive treatment by immunosuppression and respective hormone replacement.

Keywords: avelumab, hypothyroidism, hypoadrenalism, endocrinopathies, Immune Check Point Inhibitors, Pd-L1

INTRODUCTION

Programmed cell death protein 1 (also known as PD-1) is a cell surface receptor that plays a significant role in down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. PD-1 is an immune checkpoint and guards against autoimmunity through a dual mechanism of promoting apoptosis in antigen-specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (Francisco et al., 2010; Fife and Pauken, 2011). A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune system to attack tumors and are therefore used for varying success to treat some types of cancer (Syn et al., 2017). Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death ligand 1 (PD-L1) and therefore inhibits binding to its receptor the PD-1. Formation of a PD-1/PD-L1 receptor/ligand complex leads to inhibition of CD8+ T cells, and therefore inhibition of an immune-related reaction. Immunotherapy aims at ceasing this immune blockage by blocking those receptor-ligand pairs (Joseph
et al., 2018). The most common serious adverse reactions to avelumab are immune-mediated adverse reactions (irAEs) which includes rash, pneumonitis, hepatitis, colitis, endocrinopathies, and nephritis as well as life-threatening infusion reactions (Hamid et al., 2013). Hereby we present a case of hypothyroidism and adrenal insufficiency induced by Avelumab (PD-L1 inhibitor) in a 69-year-old patient with metastatic gastric cancer.

**CASE REPORT**

A 69-year male presented to us with the recurrence of gastric cancer with pancreatic metastasis. He received 6 cycles of Taxotere, Cisplatinma, and 5FU (TCF), a TCF chemotherapy regimen which includes Docetaxel, carboplatin, and 5-fluorouracil. He did not show any response to these medications. After that, he entered into a clinical trial with avelumab which is a PD-L1 inhibitor. After three months of starting avelumab, the patient started to complain of resting tachycardia. He had deranged thyroid function tests (TFT) indicating thyrotoxicosis and treated with tapazole 5 mg every other day for resting tachycardia. Subsequently, being 6 weeks on tapazole, his TFT and heart rates improved. Later, on seven months of treatment (15 cycles) the patient was complaining of fatigue, nausea, vomiting, found hypotensive (blood pressure=93/61 mm HG) and hyponatremia. At that time his relevant blood work-up was given in Table 1.

MRI, abdomen showed adrenal cortical atrophy. After getting the results of his blood tests and imaging, diagnosis of hypothyroidism and adrenal insufficiency were made and the patient was admitted to the hospital and started on hydrocortisone 20 mg in am and 10 mg in pm. Tapazole was stopped initially and later started on levothyroxine 50 mcg which titrated up to 88 mcg. Patient symptoms improved with this treatment.

**DISCUSSION**

Immune evasion is an emerging hallmark of cancer, and oncologists have long sought to connect the power of the immune system to treat cancer (Hanahan and Weinberg, 2011). In the last 5 years, inhibition of 2 immune checkpoints, PD-1 and cytotoxic T-lymophocyte-associated protein 4 (CTLA-4), have significantly changed the landscape for immunotherapy. PD-1 is an immune checkpoint receptor expressed on activated T cells. When bound by PD-L1, PD-1 causes T-cell exhaustion and a favorable environment for tumor growth (Topalian et al., 2015). Immune checkpoint inhibitors (ICIs) that block the programmed death 1 axis (PD-L1, PD-1) are important treatment options in various tumor types. Avelumab also functions as an immune checkpoint inhibitor and has recently been approved in the United States, Europe and Japan for the treatment of metastatic Merkel cell carcinoma (MCC) (Shirley, 2018). Common treatment-related adverse events (TRAEs) with anti–PD-L1/PD-1 agents include low-grade fatigue, pruritus and rash. In addition, potentially serious irAEs, such as high-grade pneumonitis or autoimmune-like side effects, occur in a minority of patients (Postow et al., 2015; Spain et al., 2016; Weber et al., 2015). The exact mechanism of PD-L1 induced endocrinopathies is not known. We suggest that

### Table 1: Relevant blood tests and their results

| Test       | Result | Reference Range | Comments                          |
|------------|--------|-----------------|-----------------------------------|
| TSH        | 24.06 U/mL | 0.35-3.5 U/mL   | Higher than normal, suggest hypothyroidism |
| FT4        | 0.63 ng/dl | 0.8-1.8 ng/dl  | Lower than normal, suggest hypothyroidism |
| Cortisol (AM) | 2.2 μg/dL | 5-25 μg/dL     | Lower than normal, Adrenal Insufficiency suspected |
| Cortisol (PM) | 0.4 μg/dL | 2-14 μg/dL     | Lower than normal                  |
cell lytic properties of this immunotherapeutic agent cause thyroiditis, and eventually lead to hypothyroidism and possible adrenalitis leading to hypoadrenalism. In some cases hypophysitis was also property, but not in our patient. On review of the literature, we found 4 studies and trials regarding the use, safety, and immune-related adverse events by the use of avelumab and other immune checkpoints inhibitors. These are shown in Table 2 below.

**Table 2:** Review of literature regarding the use, safety, and immune related adverse events (irAEs) by the use of avelumab and other immune checkpoint inhibitors

| Authors       | Aim of Study                                                                 | Study Type       | Study Summary                                                                                                                                                                                                 | Outcome                                                                                           |
|---------------|-------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Kelly et al., 2018 | The aim of trial was to study safety profile of avelumab in patients with advanced solid tumors. | A pooled analysis of data from the phase 1 JAVELIN Solid Tumor and phase 2 JAVELIN Merkel 200 clinical trials | Patients with advanced solid tumors who were enrolled in the clinical trials (phase 1 JAVELIN Solid Tumor and phase 2 JAVELIN Merkel 200) received avelumab at a dose of 10 mg/kg every two weeks. Most common treatment-related adverse events (TRAE) include fatigue, nausea and diarrhea while immune-related adverse events (irAEs) include rash, hepatitis, colitis, hypothyroidism, hyperthyroidism, and adrenal insufficiency. | This pooled analysis of patients with advanced solid tumors confirm that avelumab was well tolerated and had a manageable safety profile. Immune-related events were managed by hormone replacement therapy, and corticosteroids. |
| Hahn et al., 2017 | They analyzed the incidence of irAEs for PD-1 inhibitors and management of the common irAEs which includes colitis, endocrinopathies, hepatitis, rash, pneumonitis, nephritis as well as neurologic toxicities. | seminar article  | They evaluated the occurrence of irAEs with PD-1 and PD-L1 checkpoint inhibitors. Then, the primary focus of this seminar will be on the diagnosis and management of irAEs in patients treated with PD-1 axis inhibition. | With the exception of immune-mediated endocrinopathies, the majority of irAEs are frequently treated with immunosuppressive medications such as corticosteroids. For endocrinopathies, management includes laboratory monitoring and respective hormone replacement. |
| Sosa et al., 2018 | The aim of this article was to focus on assessment and management of immune related adverse events. | review article  | Immunotherapy by checkpoint inhibitors (ICIs) is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. Anti-CTLA-4 antibody (ipilimumab), anti-Program cell death protein 1 (PD-1), antibodies (pembrolizumab and nivolumab) and anti-PD-L1 antibodies (atezolizumab, avelumab, | Immunotherapy with ICIs has shifted the paradigm of treatment on different cancer types. These immunotherapies cause irAEs, commonly affecting the skin, colon, liver, endocrine glands or lungs. Most of these effects are manageable with corticosteroids, but some of  |
and durvalumab) have been approved for clear benefits across diverse trials. Them can be potentially fatal and require special care.

Sznol et al., 2017

They reviewed the kinds, features, and management of irAEs that may arise with the use of immune check point inhibitors (ICIs).

Review article

ICIs are now considered backbone in cancer treatment. The use of ICIs can be accompanied by irAEs that affect the skin, gastrointestinal tract, liver, and endocrine system. Immune-related endocrine events are unique when compared with other irAEs because their manifestations are often irreversible. Management includes close patient monitoring, appropriate laboratory testing, replacement of hormones, and consultation with an endocrinologist when appropriate.

An awareness of the signs and symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.

Abbreviations: immune related adverse events (irAEs), Treatment-Related Adverse Events (TRAE), immune check point inhibitors (ICIs), Program cell death protein 1 (PD-1), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-ligand 1 (PD-L1)

CONCLUSION

Patients receiving avelumab and other PD-1/PD-L1 inhibitors should be monitored for signs and symptoms of immune-mediated adverse events. With the exception of immune-mediated endocrinopathies, most immune-mediated adverse events can be treated with immunosuppression with corticosteroids. For endocrinopathies like hypothyroidism, thyroiditis, adrenal insufficiency and hypophysitis we have to monitor hormone levels and continuous respective hormone replacement.

Financial interests

None declared.

Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES

Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45–59.

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42.

Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 2017;35:701-7.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369:134–44.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.

Joseph J, Zobniw C, Davis J, Anderson J, Trinh VA. Avelumab: a review of its application in metastatic Merkel cell carcinoma. Ann Pharmacother. 2018; Epub ahead of print.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018; 124:2010-7.

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-82.
Shirley M. Avelumab: A review in metastatic Merkel cell carcinoma. Target Oncol. 2018; Epub ahead of print.

Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Therap Adv Med Oncol. 2018;10:1-11.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.

Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731–41.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70-6.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immuno-therapy for the practitioner. J Clin Oncol. 2015;33:2092-9.